Blocking TLR4 can lower CCR1 and CCR2 expression b
Post# of 148158
Meanwhile CCL5 (RANTES) controls the TLR4 upregulation of cytokine expression. So leronlimab would effectively block that.
EDSA is basing it's move to phase 3 from interim analysis on a small number of patients taken off ECMO. Which is the right move to accelerate to a trial that could result in an EUA. But results may not prove out in a larger trial.